vs

Side-by-side financial comparison of CAMDEN NATIONAL CORP (CAC) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $64.3M, roughly 2.0× CAMDEN NATIONAL CORP). Over the past eight quarters, CAMDEN NATIONAL CORP's revenue compounded faster (22.6% CAGR vs 20.8%).

Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

CAC vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
2.0× larger
ZLAB
$127.1M
$64.3M
CAC
Faster 2-yr revenue CAGR
CAC
CAC
Annualised
CAC
22.6%
20.8%
ZLAB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CAC
CAC
ZLAB
ZLAB
Revenue
$64.3M
$127.1M
Net Profit
$21.9M
Gross Margin
51.0%
Operating Margin
-54.6%
Net Margin
34.0%
Revenue YoY
17.1%
Net Profit YoY
EPS (diluted)
$1.29
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAC
CAC
ZLAB
ZLAB
Q1 26
$64.3M
Q4 25
$68.1M
$127.1M
Q3 25
$65.4M
$115.4M
Q2 25
$62.3M
$109.1M
Q1 25
$60.1M
$105.7M
Q4 24
$47.6M
$108.5M
Q3 24
$45.0M
$101.8M
Q2 24
$42.8M
$100.1M
Net Profit
CAC
CAC
ZLAB
ZLAB
Q1 26
$21.9M
Q4 25
$22.6M
Q3 25
$21.2M
$-36.0M
Q2 25
$14.1M
$-40.7M
Q1 25
$7.3M
$-48.4M
Q4 24
$14.7M
Q3 24
$13.1M
$-41.7M
Q2 24
$12.0M
$-80.3M
Gross Margin
CAC
CAC
ZLAB
ZLAB
Q1 26
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Operating Margin
CAC
CAC
ZLAB
ZLAB
Q1 26
Q4 25
41.5%
-54.6%
Q3 25
40.5%
-42.3%
Q2 25
28.5%
-50.3%
Q1 25
10.3%
-53.3%
Q4 24
38.7%
-62.6%
Q3 24
35.2%
-66.6%
Q2 24
34.7%
-76.0%
Net Margin
CAC
CAC
ZLAB
ZLAB
Q1 26
34.0%
Q4 25
33.1%
Q3 25
32.4%
-31.2%
Q2 25
22.6%
-37.3%
Q1 25
12.2%
-45.8%
Q4 24
30.8%
Q3 24
29.1%
-40.9%
Q2 24
28.0%
-80.2%
EPS (diluted)
CAC
CAC
ZLAB
ZLAB
Q1 26
$1.29
Q4 25
$1.33
$-0.05
Q3 25
$1.25
$-0.03
Q2 25
$0.83
$-0.04
Q1 25
$0.43
$-0.04
Q4 24
$1.00
$-0.09
Q3 24
$0.90
$-0.04
Q2 24
$0.81
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAC
CAC
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$689.6M
Total DebtLower is stronger
$514.4M
Stockholders' EquityBook value
$710.0M
$715.5M
Total Assets
$7.0B
$1.2B
Debt / EquityLower = less leverage
0.72×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAC
CAC
ZLAB
ZLAB
Q1 26
Q4 25
$689.6M
Q3 25
$717.2M
Q2 25
$732.2M
Q1 25
$757.3M
Q4 24
$779.7M
Q3 24
$616.1M
Q2 24
$630.0M
Total Debt
CAC
CAC
ZLAB
ZLAB
Q1 26
$514.4M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
CAC
CAC
ZLAB
ZLAB
Q1 26
$710.0M
Q4 25
$696.6M
$715.5M
Q3 25
$676.4M
$759.9M
Q2 25
$652.1M
$791.7M
Q1 25
$640.1M
$810.8M
Q4 24
$531.2M
$840.9M
Q3 24
$529.9M
$667.7M
Q2 24
$508.3M
$704.2M
Total Assets
CAC
CAC
ZLAB
ZLAB
Q1 26
$7.0B
Q4 25
$7.0B
$1.2B
Q3 25
$7.0B
$1.2B
Q2 25
$6.9B
$1.2B
Q1 25
$7.0B
$1.2B
Q4 24
$5.8B
$1.2B
Q3 24
$5.7B
$985.3M
Q2 24
$5.7B
$987.4M
Debt / Equity
CAC
CAC
ZLAB
ZLAB
Q1 26
0.72×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAC
CAC
ZLAB
ZLAB
Operating Cash FlowLast quarter
$-26.0M
Free Cash FlowOCF − Capex
$-26.7M
FCF MarginFCF / Revenue
-21.0%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAC
CAC
ZLAB
ZLAB
Q1 26
Q4 25
$63.9M
$-26.0M
Q3 25
$36.1M
$-32.0M
Q2 25
$6.0M
$-31.0M
Q1 25
$1.0M
$-61.7M
Q4 24
$60.9M
$-55.8M
Q3 24
$-14.5M
$-26.8M
Q2 24
$14.5M
$-42.2M
Free Cash Flow
CAC
CAC
ZLAB
ZLAB
Q1 26
Q4 25
$58.2M
$-26.7M
Q3 25
$35.4M
$-35.0M
Q2 25
$4.5M
$-33.9M
Q1 25
$-727.0K
$-63.2M
Q4 24
$55.4M
$-58.4M
Q3 24
$-16.2M
$-28.2M
Q2 24
$13.2M
$-42.9M
FCF Margin
CAC
CAC
ZLAB
ZLAB
Q1 26
Q4 25
85.5%
-21.0%
Q3 25
54.1%
-30.4%
Q2 25
7.3%
-31.1%
Q1 25
-1.2%
-59.9%
Q4 24
116.4%
-53.8%
Q3 24
-36.0%
-27.7%
Q2 24
30.8%
-42.9%
Capex Intensity
CAC
CAC
ZLAB
ZLAB
Q1 26
Q4 25
8.4%
0.5%
Q3 25
1.1%
2.6%
Q2 25
2.4%
2.6%
Q1 25
2.9%
1.5%
Q4 24
11.7%
2.4%
Q3 24
3.8%
1.3%
Q2 24
3.0%
0.7%
Cash Conversion
CAC
CAC
ZLAB
ZLAB
Q1 26
Q4 25
2.83×
Q3 25
1.70×
Q2 25
0.43×
Q1 25
0.14×
Q4 24
4.15×
Q3 24
-1.11×
Q2 24
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CAC
CAC

Net Interest Income$52.4M81%
Noninterest Income$12.0M19%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons